Retatrutide: A Triple Agonist's Promise for Cardiovascular-Kidney-Metabolic Syndrome
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.
Background
The Cardiovascular-Kidney-Metabolic (CKM) syndrome represents a complex and interconnected cluster of conditions, including obesity, type 2 diabetes, hypertension, and chronic kidney disease, posing an escalating global health burden. Traditional single-target pharmacological interventions often prove insufficient in comprehensively addressing the multifaceted pathology of CKM syndrome and its progression. These reviews synthesize current evidence to evaluate the potential of retatrutide, a novel triple hormone receptor agonist, in managing the broad spectrum of CKM syndrome and its core component, obesity.
Study Design
Population
Reviews synthesizing current evidence on patients with Cardiovascular-Kidney-Metabolic (CKM) syndrome, including obesity, type 2 diabetes, hypertension, and chronic kidney disease.
Intervention
Retatrutide, a novel triple hormone receptor agonist.
Outcome
The potential of retatrutide in managing the broad spectrum of CKM syndrome and its core component, obesity.